SCHEMBL688525

SCHEMBL688525

COc1ccc([C@H](CC(=O)O)NC(=O)Nc2c(O)c3c(n(Cc4c(C)cccc4Cl)c2=O)CCC3)cc1F

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 1/20 0.39
ITGAV P06756 1/20 0.39
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CTSA P10619 12/20 0.36
POLB P06746 2/20 0.35
CYP3A4 P08684 1/20 0.35
GNRHR P30968 1/20 0.35
CXCR2 P25025 1/20 0.35
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL688307 0.90 MEN1 (0.38) ITGB3ITGAVMEN1KMT2ACTSA
SCHEMBL686898 0.88 MEN1 (0.39) ITGB3ITGAVMEN1KMT2ACTSA
SCHEMBL687452 0.88 KMT2A (0.38) MEN1KMT2APOLBALDH1A1HPGD
SCHEMBL688537 0.87 KEAP1 (0.39) ITGB3ITGAVMEN1KMT2AALDH1A1
SCHEMBL686847 0.87 CTSA (0.40) ITGB3ITGAVMEN1KMT2ACTSA
SCHEMBL687910 0.87 MEN1 (0.39) ITGB3MEN1KMT2ACTSAALDH1A1
SCHEMBL688106 0.87 KMT2A (0.41) MEN1KMT2ACTSAALDH1A1HPGD
SCHEMBL687500 0.87 SMN1; SMN2 (0.37) ITGB3ITGAVMEN1KMT2APOLB
SCHEMBL688395 0.87 MEN1 (0.37) ITGB3ITGAVMEN1KMT2ACTSA
SCHEMBL687271 0.86 KMT2A (0.39) ITGB3ITGAVMEN1KMT2ACTSA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1203766-B1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC (US) 2012-02-29 EP disclosed
EP-1203766-A2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors TEXAS BIOTECHNOLOGY CORPORATION (US) 2002-05-08 EP disclosed